{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:26:01Z","timestamp":1783571161326,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,1,27]],"date-time":"2012-01-27T00:00:00Z","timestamp":1327622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s11914-011-0084-x","type":"journal-article","created":{"date-parts":[[2012,1,26]],"date-time":"2012-01-26T11:59:40Z","timestamp":1327579180000},"page":"80-85","source":"Crossref","is-referenced-by-count":13,"title":["Oral Calcitonin"],"prefix":"10.1007","volume":"10","author":[{"given":"Michael J.","family":"Maricic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,1,27]]},"reference":[{"key":"84_CR1","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1126\/science.134.3495.2038","volume":"134","author":"DH Copp","year":"1961","unstructured":"Copp DH, Cameron EC. Demonstration of a hypocalcemic factor (calcitonin) in commercial parathyroid extract. Science. 1961;134:2038.","journal-title":"Science."},{"key":"84_CR2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/BF00301940","volume":"57","author":"M Azria","year":"1995","unstructured":"Azria M, Copp DH, Zanelli JM. 25\u00a0years of salmon calcitonin: from synthesis to therapeutic use [editorial]. Calcif Tissue Int. 1995;57:405\u20138.","journal-title":"Calcif Tissue Int"},{"key":"84_CR3","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1359\/jbmr.2002.17.8.1478","volume":"17","author":"R Buclin","year":"2002","unstructured":"Buclin R, Rochat MC, Burckhardt P, et al. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Min Res. 2002;17:1478\u201385.","journal-title":"J Bone Min Res"},{"key":"84_CR4","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/1529-0131(199906)42:6<1159::AID-ANR12>3.0.CO;2-Q","volume":"42","author":"DH Manicourt","year":"1999","unstructured":"Manicourt DH, Altman RD, Williams JM, et al. Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. Arthritis Rheum. 1999;42:1159\u201367.","journal-title":"Arthritis Rheum"},{"key":"84_CR5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bone.2005.04.032","volume":"37","author":"YZ Bagger","year":"2005","unstructured":"Bagger YZ, Tanko LB, Alexandersen P, et al. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone. 2005;37:425\u201330.","journal-title":"Bone"},{"key":"84_CR6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1172\/JCI112584","volume":"78","author":"G Nicholson","year":"1986","unstructured":"Nicholson G, Moseley J, Sexton P, Mendelsohn F, Martin T. Abundant calcitonin receptors in isolate rat osteoclasts, biochemical, and autoradiographic characterization. J Clin Invest. 1986;78:355\u201360.","journal-title":"J Clin Invest."},{"issue":"5","key":"84_CR7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/BF02555225","volume":"41","author":"T Buclin","year":"1987","unstructured":"Buclin T, Randin J, Jacquet A, et al. The effect of rectal and nasal administration of salmon calcitonin in normal subjects. Calcif Tissue Int. 1987;41(5):252\u20138.","journal-title":"Calcif Tissue Int."},{"issue":"1","key":"84_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-001-1135-6","volume":"74","author":"SH Ralston","year":"2004","unstructured":"Ralston SH, Coleman R, Fraser WD, et al. Medical management of hypercalcemia. Calcif Tissue Int. 2004;74(1):1\u201311.","journal-title":"Calcif Tissue Int."},{"issue":"6862","key":"84_CR9","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/bmj.305.6862.1124","volume":"305","author":"JA Kanis","year":"1992","unstructured":"Kanis JA, Johnell O, Gullberg B, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ. 1992;305(6862):1124\u20138.","journal-title":"BMJ."},{"key":"84_CR10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1210\/jcem-72-2-344","volume":"72","author":"K Overgaard","year":"1991","unstructured":"Overgaard K, Agnusdei D, Hansen MA, et al. Dose response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab. 1991;72:344\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"84_CR11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","volume":"109","author":"CH Chesnut","year":"2000","unstructured":"Chesnut CH, Silverman SL, Andriano K, for the Proof Study Group, et al. Prospective. Randomized trial of nasal spray calcitonin in postmenopausal women with established osteoporosis: the PROOF study. Am J Med. 2000;109:267\u201376.","journal-title":"Am J Med"},{"key":"84_CR12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jc.85.1.231","volume":"851","author":"RD Wasnich","year":"2000","unstructured":"Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 2000;851:231\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"84_CR13","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637\u201345.","journal-title":"JAMA"},{"key":"84_CR14","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1056\/NEJMoa1010650","volume":"364","author":"J Schilcher","year":"2011","unstructured":"Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011;364:1727\u201338.","journal-title":"N Engl J Med"},{"key":"84_CR15","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Karsdal MA, Henriksen K, Bay-Jensen AC, et al.Lessons learned from the development of oral calcitonin : The first tablet formulation of a protein in Phase III clinical trials. J Clin Pharmacol 2011 51: 460-71. This is an excellent review of the challenges posed in the absorption or oral peptides, and the methods developed to overcome them.","DOI":"10.1177\/0091270010372625"},{"key":"84_CR16","doi-asserted-by":"crossref","unstructured":"\u2022 Henriksen K, Bay-Jensen AC, Christiansen C, et al. Oral salmon calcitonion- pharmacology in osteoporosis. Expert Opin Biol Ther 2010;10:1617-29. This is a comprehensive overview of the clinical development of oral calcitonin.","DOI":"10.1517\/14712598.2010.526104"},{"key":"84_CR17","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1021\/jm00021a014","volume":"38","author":"A Leone-Bay","year":"1995","unstructured":"Leone-Bay A, McInnes C, Wang N, et al. Microsphere formation in a series of derivatized alpha-amino acids: properties, molecular modeling, and oral delivery of salmon calcitonin. J Med Chem. 1995;38:4257\u201362.","journal-title":"J Med Chem."},{"key":"84_CR18","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1021\/jm00021a015","volume":"38","author":"A Leone-Bay","year":"1995","unstructured":"Leone-Bay A, Santiago N, Achan D, et al. N-acylated alpha amino acids as novel oral delivery agents for proteins. J Med Chem. 1995;38:4263\u20139.","journal-title":"J Med Chem."},{"key":"84_CR19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1472-6904-8-5","volume":"8","author":"MA Karsdal","year":"2008","unstructured":"Karsdal MA, Byrjalsen I, Riis BJ, et al. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of salmon calcitonin. BMC Clin Pharmacol. 2008;8:5.","journal-title":"BMC Clin Pharmacol."},{"key":"84_CR20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00228-009-0735-3","volume":"66","author":"MA Karsdal","year":"2010","unstructured":"Karsdal MA, Byrjalsen I, Henriksen K, et al. Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy. Eur J Clin Pharmacol. 2010;66:29\u201337.","journal-title":"Eur J Clin Pharmacol."},{"key":"84_CR21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1472-6904-8-12","volume":"8","author":"MA Karsdal","year":"2008","unstructured":"Karsdal MA, Byrjalsen I, Riis BJ, et al. Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin. BMC Clin Pharmacol. 2008;8:12.","journal-title":"BMC Clin Pharmacol."},{"key":"84_CR22","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1359\/JBMR.040715","volume":"19","author":"LB Tanko","year":"2004","unstructured":"Tanko LB, Bagger YZ, Alexandersen P, et al. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res. 2004;19:1531\u20138.","journal-title":"J Bone Miner Res"},{"key":"84_CR23","unstructured":"Russo LA, Lau E, Tang H, et al. Efficacy and safety of oral salmon calcitonin in postmenopausal osteoporosis: Randomized, double-blind, placebo-controlled trial. Abstract. American Society of Bone and Mineral Research Annual Meeting. Toronto, 2010."},{"key":"84_CR24","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.joca.2008.01.014","volume":"16","author":"MA Karsdal","year":"2008","unstructured":"Karsdal MA, Leeming DJ, Dam EB, et al. Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage. 2008;16:638\u201346.","journal-title":"Osteoarthritis Cartilage"},{"key":"84_CR25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.berh.2009.08.004","volume":"24","author":"TS Kwan","year":"2010","unstructured":"Kwan TS, Lajeunesse D, Pelletier JP, et al. Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol. 2010;24:51\u201370.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"3","key":"84_CR26","first-page":"285","volume":"5","author":"DH Manicourt","year":"2005","unstructured":"Manicourt DH, Devogelaer JP, Azria M, et al. Rationale for the potential use of calcitonin in osteoarthritis. J Musculoskelet Neuronal Interact. 2005;5(3):285\u201393.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"84_CR27","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bone.2005.04.032","volume":"37","author":"YZ Bagger","year":"2005","unstructured":"Bagger YZ, Tanko LB, Alexanderson P. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone. 2005;37:425\u201330.","journal-title":"Bone"},{"key":"84_CR28","doi-asserted-by":"crossref","unstructured":"Karsdal MA, Alexandersen P, Dam EB, et al. Oral calcitonin demonstrated symptom-modifying efficacy and decreased cartilage volume loss: Results from a 2-year Phase 3 trial in patients with osteoarthritis of the knee. Abstract L9. American College of Rheumatology National Meeting. Chicago. 2011","DOI":"10.1016\/S1063-4584(11)60091-5"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-011-0084-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-011-0084-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-011-0084-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T23:26:25Z","timestamp":1561245985000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-011-0084-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,27]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["84"],"URL":"https:\/\/doi.org\/10.1007\/s11914-011-0084-x","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,27]]}}}